Claims for Patent: 6,352,856

Summary for Patent: 6,352,856

Title:	Chimeric poxvirus comprising sequences of a retroviral vector component
Abstract:	A chimeric poxvirus is disclosed, which comprises the sequences of the vector component of a retroviral vector particle and optionally the packaging component of a defective retroviral particle. The chimeric poxvirus according to the invention particularly can be used for applications in gene therapy or tumor therapy.
Inventor(s):	Falkner; Falko-Guenter (Orth/Donau, AT), Holzer; Georg (Vienna, AT), Dorner; Friedrich (Vienna, AT)
Assignee:	Baxter Vaccine AG (Vienna, AT)
Application Number:	09/228,625
Patent Claims:	1. A chimeric poxvirus comprising a poxvirus genome comprising stably inserted therein a replication defective retroviral proviral genome under transcriptional control of a promoter, wherein a foreign gene sequence under transcriptional control of a promoter is inserted into said retroviral genome. 2. The chimeric poxvirus as set forth in claim 1, further comprising a packaging component sequence. 3. A chimeric poxvirus as set forth in claim 1, wherein said poxvirus is a chordopox virus. 4. A chimeric poxvirus as set forth in claim 1, wherein said poxvirus is an orthopox virus. 5. A chimeric poxvirus as set forth in claim 4, wherein said orthopox virus is a vaccinia virus. 6. A chimeric poxvirus as set forth in claim 6, wherein said vaccinia virus is a defective vaccinia virus. 7. The chimeric poxvirus as set forth in claim 1, wherein said retroviral genome is under transcriptional control of a poxvirus promoter. 8. The chimeric poxvirus as set forth in claim 2, wherein said packaging component sequence is under transcriptional control of a poxvirus promoter. 9. The chimeric poxvirus as set forth in claim 7, wherein said poxvirus promoter is an early poxvirus promoter. 10. A chimeric poxvirus as set forth in claim 8, wherein said poxvirus promoter is an early poxvirus promoter. 11. The chimeric poxvirus as set forth in claim 1, wherein said retroviral genome sequence comprises introns. 12. The chimeric poxvirus as set forth in claim 1, wherein said retroviral genome sequence comprises an internal polyadenylation sequence. 13. A defective retroviral particle comprising an intron-containing genome. 14. A method for producing a defective retroviral particle comprising a foreign gene sequence, wherein the method comprises infecting a cell of a packaging cell line with a chimeric poxvirus comprising a poxvirus genome having stably inserted therein a replication defective retroviral genome under transcriptional control of a promoter, wherein a foreign gene sequence under transcriptional control of a promoter is inserted into said retroviral genome, and wherein the infected cell produces a defective retroviral particle. 15. A method for producing a defective retroviral particle comprising a foreign gene sequence, wherein the method comprises infecting a cell of a cell line with a chimeric poxvirus comprising a poxvirus genome having stably inserted therein a replication defective retroviral genome under transcriptional control of a promoter, wherein a foreign gene sequence under transcriptional control of a promoter is inserted into said retroviral genome and retroviral packaging components under transcriptional control of a promoter, and wherein the infected cell produces a defective retroviral particle.

Details for Patent 6,352,856

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-01-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-01-16
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-01-16